CORR Insights®: Isolated Limb Perfusion Can Avert Amputation Indication in Initially Nonsalvageable Sarcomas of the Extremities

Where Are We Now?

Isolated limb perfusion (ILP) with tumor necrosis factor-alpha (TNF-α) and melphalan (TM-ILP) is a regional chemotherapy technique used to treat locally advanced or in-transit melanoma and soft tissue sarcomas of the limbs. The technique involves temporary isolation of circulating blood in an affected limb using a tourniquet and vascular cannulation. A high-dose of chemotherapy, typically melphalan combined with TNF-α, is then perfused through the limb using an extracorporeal circuit. Hyperthermia (39°C to 41°C) is also employed to enhance the cytotoxic effects. This technique is typically reserved for patients with tumors that are considered unresectable because of extensive local tumor burden, involvement of critical neurovascular structures, or situations where resection would result in a defect too large for adequate soft tissue reconstruction. The addition of TNF-α increases vascular permeability and selectively targets tumor vasculature. Combined with hyperthermia, it enhances melphalan delivery and improves tumor response. Because the treatment is confined to the limb, it permits higher drug concentrations than systemic chemotherapy with fewer systemic side effects.

The use of high-dose cytotoxic agents, however, and the procedure’s invasiveness pose risks. Local complications may include erythema, tissue necrosis, delayed wound healing, neuropathy, and compartment syndrome. Systemic complications include chemotherapy leakage, inflammatory responses, bone marrow suppression, and renal or hepatic toxicity. Vascular injury, thromboembolism, sepsis, and anesthetic complications are also possible [5]. In addition, long-term effects may involve chronic lymphedema, nonhealing ulcers, muscle atrophy, joint contractures, persistent neuropathy, and, rarely, secondary malignancies [2].

In this retrospective, single-institution study by Lesensky et al. [6], published in this month’s Clinical Orthopaedics and Related Research®, a total of 34 patients with locally advanced soft tissue sarcomas were treated with TM-ILP. This technique resulted in a limb-sparing option for most patients with advanced or borderline resectable extremity soft tissue sarcomas that would otherwise be treated with amputation for local disease control. Most patients underwent successful limb-sparing surgery with encouraging short- to midterm limb preservation rates (87% at 12 months). The authors concluded that TM-ILP was generally safe, with no major early complications, though technical challenges and occasional drug leakage occurred. Based on these findings, sarcoma centers with ILP programs should consider refining the indications of this approach and expanding its use in select patients. Centers without ILP should consider investing in program development to offer this option for patients with advanced local disease. The procedure requires specialized expertise beyond “standard” sarcoma care but presents an exciting and challenging opportunity to develop or expand a needed service for a select group of patients with advanced local disease, where current therapies—radiation, conventional chemotherapy, and surgery—are often insufficient for achieving local tumor control. Given the emphasis on multidisciplinary care in cancer programs, ILP represents an ideal opportunity for such efforts.

Where Do We Need to Go?

The study by Lesensky and colleagues [6] highlights an ongoing challenge in orthopaedic oncology: achieving disease control in patients with advanced local tumors. TM-ILP appears to be a viable option for select patients in whom tumor-free margins and functional preservation are unattainable with surgery, radiation, or standard chemotherapy, and amputation is the only alternative. The outcomes align with other TM-ILP series [1, 7], supporting its potential as a limb-sparing strategy in carefully selected patients, though results are not broadly generalizable. Its use in the United States remains limited because of procedural complexity and licensing and patent rights restrictions on TNF-α use.

Future studies should seek to support or refute the findings of Lesensky et al. [6]. First, efforts should focus on collaborative, prospective studies that acknowledge the rarity of this condition and limited patient population. These studies should clearly define unresectability criteria to reduce selection bias, standardize adjuvant therapies, and prioritize long-term follow-up to capture late oncologic events and patient-reported outcomes.

ILP has been used in Europe with success and acceptable levels of risk and adverse effects [1, 2, 6, 7]. It has been shown that, when used with melphalan in the setting of ILP, measured clinical responses are achievable [4]. To this end, efforts to petition the FDA for clinical approval, even on a compassionate basis, are necessary. Why shouldn’t our patients have an opportunity to benefit from a therapy that can achieve good oncologic and functional outcomes?

How Do We Get There?

Understanding the capabilities and limitations of TM-ILP is an important first step in applying and extending the applications of this therapeutic modality. The preliminary study in CORR® [6] suggests that TM-ILP may offer a valuable limb-preserving option for select patients with unresectable sarcomas. Based on these findings, dedicated sarcoma centers should lead efforts to expand access to TM-ILP by refining patient selection, improving delivery methods, and offering training to interested oncology surgeons and other healthcare professionals. Centers without ILP should consider investing in program development to offer this treatment for patients with advanced local disease. Given the emphasis on multidisciplinary care in cancer programs, ILP represents an ideal opportunity for such collaboration.

Prospective, multicenter studies with defined indications, standardized adjuvant therapies, and appropriate cohorts are needed to validate and expand the role of TM-ILP in multimodal sarcoma care, with emphasis on oncologic, functional, and quality-of-life outcomes. This can only be achieved by cooperative studies across institutions. There are a number of cooperative cancer groups in the United States and societies such as the Musculoskeletal Tumor Society that collectively can meet this challenge.

Read This Next

• This study compared the use of TM-ILP to the standard treatment of locally recurrent soft tissue extremity sarcoma; TM-ILP provided superior local disease control in patients with recurrent sarcoma compared with standard therapy [3].

• Global health status and quality of life in patients treated with TM-ILP were comparable to those of the general population and patients who underwent amputation but higher than that observed in a general cancer population [8].

• TM-ILP achieved high response rates in soft tissue sarcomas, with responses appearing to correlate with microvessel density in biopsy specimens; given the heterogeneity of sarcomas, some histologic subtypes responded well to TM-ILP, while others did not [4].